These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 7551920

  • 1. Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research.
    Crinò L, Clerici M, Figoli F, Barduagni M, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Di Costanzo F.
    Lung Cancer; 1995 Apr; 12 Suppl 1():S125-32. PubMed ID: 7551920
    [Abstract] [Full Text] [Related]

  • 2. Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
    Crinò L, Clerici M, Figoli F, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Di Costanzo F, Boni C.
    Ann Oncol; 1995 Apr; 6(4):347-53. PubMed ID: 7619749
    [Abstract] [Full Text] [Related]

  • 3. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
    Rosell R, Abad-Esteve A, Moreno I, Barnadas A, Carles J, Fernandez C, Ribelles N, Culubret M.
    Cancer; 1990 Apr 15; 65(8):1692-9. PubMed ID: 2156597
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
    Gebbia V, Galetta D, Riccardi F, Gridelli C, Durini E, Borsellino N, Gebbia N, Valdesi M, Caruso M, Valenza R, Pezzella G, Colucci G, Gruppo Oncologico Italia Meridionale.
    Lung Cancer; 2002 Aug 15; 37(2):179-87. PubMed ID: 12140141
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
    Cok G, Göksel T, Soyer S, Atil H, Güzelant A, Aysan T.
    Tuberk Toraks; 2006 Aug 15; 54(2):161-7. PubMed ID: 16924573
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
    Comella P, Frasci G, Panza N, Manzione L, Lorusso V, Di Rienzo G, Cioffi R, De Cataldis G, Maiorino L, Bilancia D, Nicolella G, Natale M, Carpagnano F, Pacilio C, De Lena M, Bianco A, Comella G.
    J Clin Oncol; 1999 May 15; 17(5):1526-34. PubMed ID: 10334540
    [Abstract] [Full Text] [Related]

  • 12. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
    Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Wenger M, Lange W, Mertelsmann R.
    Ann Oncol; 1997 Jan 15; 8(1):57-64. PubMed ID: 9093708
    [Abstract] [Full Text] [Related]

  • 13. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).
    Baldini E, Tibaldi C, Ardizzoni A, Salvati F, Antilli A, Portalone L, Barbera S, Romano F, De Marinis F, Migliorino MR, Noseda MA, Borghini U, Crippa M, Ferrara G, Raimondi M, Fioretti M, Bandera M, Pennucci MC, Galeasso G, Cacciani GC, Lepidini G, Sunseri G, Lanfranco C, Rinaldi M, Rosso R.
    Br J Cancer; 1998 Jun 15; 77(12):2367-70. PubMed ID: 9649160
    [Abstract] [Full Text] [Related]

  • 14. European experience with ifosfamide in non-small cell lung cancer.
    Drings P.
    Semin Oncol; 1989 Feb 15; 16(1 Suppl 3):22-30. PubMed ID: 2539645
    [Abstract] [Full Text] [Related]

  • 15. Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. ONCOPAZ Cooperative Group.
    González Barón M, Feliu J, Espinosa E, García Girón C, Blanco E, Garrido P, Colmenarejo A, Ordóñez A, Moyano A, de la Gándara I.
    Ann Oncol; 1994 Apr 15; 5(4):323-7. PubMed ID: 8075028
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.
    Crinò L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Bianco R, Marangolo M, Di Costanzo F, Sassi M, Barni S, Ravaioli A, Adamo V, Portalone L, Cruciani G, Masotti A, Ferrara G, Gozzelino F, Tonato M.
    J Clin Oncol; 1999 Nov 15; 17(11):3522-30. PubMed ID: 10550150
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer.
    Gridelli C, Pepe R, Palmeri S, Iacobelli S, Gentile M, Gebbia V, Garufi C, Airoma G, Palmieri G, Russo A.
    Cancer Chemother Pharmacol; 1991 Nov 15; 28(5):405-7. PubMed ID: 1655301
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.